- Trial Phase
- Preclinical / Early-stage (no clinical trials identified)
- Time to Market
- Unknown — BA3142 is preclinical/early-stage with no disclosed clinical development timeline. Given BioAtla's financial distress and strategic review, development is likely paused or delayed indefinitely.
- Why 1/10
- No hard, dated catalyst exists for BA3142 in the next ~12 months. The drug is an early-stage pipeline asset at a company in severe financial distress with a going concern warning. The company's strategic alternatives process (asset sales, M&A, or wind-down) is the relevant binary event, not any BA3142-specific readout or regulatory decision.
BA3142 is a preclinical/early-stage pipeline asset at BioAtla, which is in severe financial distress with only $1.5M cash, a going concern warning, and a formal strategic alternatives process underway. The drug has no near-term catalysts, and the company's survival — not any single pipeline asset — is the primary investor concern. Watch for the outcome of the strategic review (asset sales, M&A, or wind-down) rather than any BA3142-specific developments.
Price Chart
Executive Summary
BA3142 is an early-stage conditionally active biologic (CAB) antibody candidate in BioAtla's pipeline for solid tumor cancers. The drug is preclinical/early-stage with no publicly disclosed molecular target, no clinical trial data, and no near-term catalysts. Critically, BioAtla (BCAB, OTCQB) is in severe financial distress — only $1.5M cash, a going concern warning, delisted from Nasdaq, 70% workforce reduction, and a formal strategic alternatives process underway. The company's survival is the primary investor concern, not any single pipeline asset. BA3142 has negligible standalone value in this context.
How It Works
BA3142 is a conditionally active biologic (CAB) antibody being developed by BioAtla for solid tumor cancers. CABs are designed to be active only in the acidic tumor microenvironment while remaining inactive in healthy tissue, potentially reducing side effects compared to conventional cancer antibodies. The specific molecular target of BA3142 has not been publicly disclosed.
Trial Status
No clinical trials for BA3142 were identified in any internal or external database. BioAtla's pipeline is paused pending the outcome of the company's strategic alternatives process, which was initiated in March 2026 alongside a 70% workforce reduction.
The Two-Sided Case
Upcoming Catalysts
- Outcome of BioAtla's strategic alternatives process (asset sales, M&A, partnership, or wind-down) — no set date
- Potential Advance Notice deliveries under the Yorkville SEPA (would signal cash needs and dilution)
- Q3 2026 earnings report expected Nov 11, 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BioAtla, Inc. S-1 BCAB ·Originating report